LIGAND PHARMACEUTICALS INC (LGNDZ)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 40M 80M 120M Q3 '21: 64.8M Q4 '21: 56.4M Q1 '22: 36.5M Q2 '22: 50.1M Q3 '22: 59.2M Q4 '22: 50.4M Q1 '23: 44M Q2 '23: 26.4M Q3 '23: 32.9M Q4 '23: 28.1M Q1 '24: 31M Q2 '24: 41.5M Q3 '24: 51.8M Q4 '24: 42.8M Q1 '25: 45.3M Q2 '25: 47.6M Q3 '25: 115.5M Q4 '25: 59.7M Q1 '26: 51.7M Q2 '26: 63.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 35M 70M 105M Q1 '17: 55.8M Q2 '17: 89.1M Q3 '17: 43.3M Q4 '17: 57.9M Q1 '18: 55.4M Q2 '18: 88.9M Q3 '18: 44.2M Q4 '18: 56.6M Q1 '19: 39.6M Q2 '19: 22.6M Q3 '19: 21.7M Q1 '17 Q3 '17 Q1 '18 Q3 '18 Q1 '19 Q3 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-40M -20M 0 20M 40M 60M Q2 '21: 45.7M Q3 '21: 15.7M Q4 '21: 37.7M Q1 '22: 2.1M Q2 '22: 8.7M Q3 '22: 12.3M Q1 '23: 14.2M Q2 '23: -2M Q3 '23: 3.1M Q4 '23: -3.4M Q1 '24: 3M Q2 '24: -19.1M Q3 '24: 3.1M Q4 '24: -9.6M Q1 '25: -36.2M Q2 '25: 8.4M Q3 '25: 54.9M Q4 '25: 13.8M Q1 '26: 17.4M Q2 '26: 8.6M Q3 '21 Q2 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-80M -40M 0 40M 80M 120M Q3 '21: 13.7M Q4 '21: -5.4M Q1 '22: -15.4M Q2 '22: -895K Q3 '22: 404K Q4 '22: -17.5M Q1 '23: 41.9M Q2 '23: 2.3M Q3 '23: -10.3M Q4 '23: 18.2M Q1 '24: 86.1M Q2 '24: -51.9M Q3 '24: -7.2M Q4 '24: -31.1M Q1 '25: -42.5M Q2 '25: 4.8M Q3 '25: 117.3M Q4 '25: 44.8M Q1 '26: -13.3M Q2 '26: 48.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 1.5M 3M 4.5M Q1 '17: 340K Q2 '17: 903K Q3 '17: 2.4M Q4 '17: 1.7M Q1 '18: 788K Q2 '18: 1.1M Q3 '18: 1.5M Q4 '18: 3M Q1 '19: 3.9M Q2 '19: 2.4M Q3 '19: 3.1M Q1 '17 Q3 '17 Q1 '18 Q3 '18 Q1 '19 Q3 '19

Operating Cash Flow Quarterly

-40M -20M 0 20M 40M 60M Q3 '21: 20M Q4 '21: 27.6M Q1 '22: 52M Q2 '22: 11.9M Q3 '22: 20.5M Q4 '22: 53.5M Q1 '23: 33.9M Q2 '23: -82K Q3 '23: 7.6M Q4 '23: 8.1M Q1 '24: 18.7M Q2 '24: 13.3M Q3 '24: 36.5M Q4 '24: 28.5M Q1 '25: -25.4M Q2 '25: 15.8M Q3 '25: 13.1M Q4 '25: 45.9M Q1 '26: 48.7M Q2 '26: 24M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-40M -20M 0 20M 40M 60M Q3 '21: 18.3M Q4 '21: 25.4M Q1 '22: 47.1M Q2 '22: 5.3M Q3 '22: 16.2M Q4 '22: 51.3M Q1 '23: 31.5M Q2 '23: -285K Q3 '23: 7.2M Q4 '23: 7.6M Q1 '24: 18.6M Q2 '24: 12.9M Q3 '24: 35.9M Q4 '24: 27.8M Q1 '25: -25.7M Q2 '25: 15.6M Q3 '25: 13.1M Q4 '25: 45.9M Q1 '26: 48.5M Q2 '26: 24M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 8M 16M 24M Q4 '20: 16.7M Q1 '21: 17.2M Q2 '21: 17.2M Q3 '21: 17.1M Q4 '21: 16.7M Q1 '22: 16.8M Q2 '22: 17.1M Q3 '22: 17.1M Q4 '22: 16.9M Q1 '23: 18M Q2 '23: 17.7M Q3 '23: 17.4M Q1 '24: 18.1M Q2 '24: 18M Q3 '24: 18.4M Q1 '25: 19.2M Q2 '25: 19.9M Q3 '25: 20.6M Q1 '26: 19.9M Q2 '26: 21.8M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q3 '20: -0.99 Q4 '20: -0.21 Q1 '21: 2.30 Q2 '21: 2.77 Q3 '21: 3.99 Q4 '22: -1.99 Q1 '23: 1.25 Q2 '23: 1.43 Q3 '23: 0.82 Q4 '23: 2.90 Q1 '24: 5.32 Q2 '24: 2.31 Q3 '24: 2.51 Q4 '24: -0.22 Q1 '25: -7.18 Q2 '25: -4.06 Q3 '25: 2.01 Q4 '25: 5.89 Q1 '26: 7.43 Q2 '26: 9.41 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.